A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer

AbstractAimAnti-Müllerian hormone (AMH) shows promise as a biomarker of the ovarian reserve but current assays are insufficiently sensitive to allow assessment of this post-chemotherapy in most women. We have assessed a new highly sensitive AMH assay (Ansh picoAMH) in the evaluation of ovarian activity in women with very low ovarian reserve after chemotherapy.MethodsA prospective cohort and an independent validation cohort of premenopausal women with early breast cancer (eBC) were recruited at the time of diagnosis (combined n=98), and ovarian reserve markers 2–5years later following chemotherapy were assessed in relation to menstrual activity.ResultsThe picoAMH assay had a limit of detection of 7.5pg/ml. AMH clearly distinguished women with ongoing menses from those with amenorrhoea at 2years after diagnosis (mean 522±169 versus 8.9±1.3pg/ml, P